218 related articles for article (PubMed ID: 28345629)
21. Mechanisms of resistance to cabazitaxel.
Duran GE; Wang YC; Francisco EB; Rose JC; Martinez FJ; Coller J; Brassard D; Vrignaud P; Sikic BI
Mol Cancer Ther; 2015 Jan; 14(1):193-201. PubMed ID: 25416788
[TBL] [Abstract][Full Text] [Related]
22. Breast cancer cells respond differently to docetaxel depending on their phenotype and on survivin upregulation.
De Iuliis F; Salerno G; Giuffrida A; Milana B; Taglieri L; Rubinacci G; Giantulli S; Terella F; Silvestri I; Scarpa S
Tumour Biol; 2016 Feb; 37(2):2603-11. PubMed ID: 26392111
[TBL] [Abstract][Full Text] [Related]
23. The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells.
Wang L; Wang ZY
Oncol Rep; 2010 Apr; 23(4):1109-17. PubMed ID: 20204298
[TBL] [Abstract][Full Text] [Related]
24. The zinc finger domain of Wilms' tumor 1 suppressor gene (WT1) behaves as a dominant negative, leading to abrogation of WT1 oncogenic potential in breast cancer cells.
Han Y; San-Marina S; Yang L; Khoury H; Minden MD
Breast Cancer Res; 2007; 9(4):R43. PubMed ID: 17634147
[TBL] [Abstract][Full Text] [Related]
25. Wilms' tumor 1 (
Han Y; Song C; Zhang T; Zhou Q; Zhang X; Wang J; Xu B; Zhang X; Liu X; Ying X
Cell Cycle; 2020 Oct; 19(20):2662-2675. PubMed ID: 32892698
[TBL] [Abstract][Full Text] [Related]
26. Epithelial-to-mesenchymal transition mediates docetaxel resistance and high risk of relapse in prostate cancer.
Marín-Aguilera M; Codony-Servat J; Reig Ò; Lozano JJ; Fernández PL; Pereira MV; Jiménez N; Donovan M; Puig P; Mengual L; Bermudo R; Font A; Gallardo E; Ribal MJ; Alcaraz A; Gascón P; Mellado B
Mol Cancer Ther; 2014 May; 13(5):1270-84. PubMed ID: 24659820
[TBL] [Abstract][Full Text] [Related]
27. The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis.
Chau YY; Hastie ND
Trends Genet; 2012 Oct; 28(10):515-24. PubMed ID: 22658804
[TBL] [Abstract][Full Text] [Related]
28. WT1 represses HOX gene expression in the regulation of gynaecologic tumour histologic type.
Andikyan V; Taylor HS
J Cell Mol Med; 2009; 13(11-12):4522-31. PubMed ID: 19017365
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of melatonin on hypoxia-induced vasculogenic mimicry via suppressing epithelial-mesenchymal transition (EMT) in breast cancer stem cells.
Maroufi NF; Amiri M; Dizaji BF; Vahedian V; Akbarzadeh M; Roshanravan N; Haiaty S; Nouri M; Rashidi MR
Eur J Pharmacol; 2020 Aug; 881():173282. PubMed ID: 32580038
[TBL] [Abstract][Full Text] [Related]
30. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
31. High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer.
Qi XW; Zhang F; Yang XH; Fan LJ; Zhang Y; Liang Y; Ren L; Zhong L; Chen QQ; Zhang KY; Zang WD; Wang LS; Zhang Y; Jiang J
Oncol Rep; 2012 Oct; 28(4):1231-6. PubMed ID: 22797561
[TBL] [Abstract][Full Text] [Related]
32. Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that have undergone BMP2/RUNX2 signaling pathway induction.
Tan CC; Li GX; Tan LD; Du X; Li XQ; He R; Wang QS; Feng YM
Oncotarget; 2016 Nov; 7(48):79688-79705. PubMed ID: 27806311
[TBL] [Abstract][Full Text] [Related]
33. Epithelial-to-mesenchymal transition leads to docetaxel resistance in prostate cancer and is mediated by reduced expression of miR-200c and miR-205.
Puhr M; Hoefer J; Schäfer G; Erb HH; Oh SJ; Klocker H; Heidegger I; Neuwirt H; Culig Z
Am J Pathol; 2012 Dec; 181(6):2188-201. PubMed ID: 23041061
[TBL] [Abstract][Full Text] [Related]
34. HDAC8 suppresses the epithelial phenotype and promotes EMT in chemotherapy-treated basal-like breast cancer.
Pantelaiou-Prokaki G; Mieczkowska I; Schmidt GE; Fritzsche S; Prokakis E; Gallwas J; Wegwitz F
Clin Epigenetics; 2022 Jan; 14(1):7. PubMed ID: 35016723
[TBL] [Abstract][Full Text] [Related]
35. The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.
Satram-Maharaj T; Nyarko JN; Kuski K; Fehr K; Pennington PR; Truitt L; Freywald A; Lukong KE; Anderson DH; Mousseau DD
Cell Signal; 2014 Dec; 26(12):2621-32. PubMed ID: 25152370
[TBL] [Abstract][Full Text] [Related]
36. Isoforms of Wilms' tumor suppressor gene (WT1) have distinct effects on mammary epithelial cells.
Burwell EA; McCarty GP; Simpson LA; Thompson KA; Loeb DM
Oncogene; 2007 May; 26(23):3423-30. PubMed ID: 17160023
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-451 induces epithelial-mesenchymal transition in docetaxel-resistant lung adenocarcinoma cells by targeting proto-oncogene c-Myc.
Chen D; Huang J; Zhang K; Pan B; Chen J; De W; Wang R; Chen L
Eur J Cancer; 2014 Nov; 50(17):3050-67. PubMed ID: 25310895
[TBL] [Abstract][Full Text] [Related]
38. Wilms' tumour gene 1 (WT1) as a target in curcumin treatment of pancreatic cancer cells.
Glienke W; Maute L; Wicht J; Bergmann L
Eur J Cancer; 2009 Mar; 45(5):874-80. PubMed ID: 19196508
[TBL] [Abstract][Full Text] [Related]
39. GRIM19 is involved in WT1 expression and epithelial-to-mesenchymal transition in adenomyotic lesions.
Geng C; Liu HR; Zhao Y; Yang Y; Chao L
Reproduction; 2021 Oct; 162(5):385-395. PubMed ID: 34590585
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic utility of Wilms' tumour-1 protein (WT-1) immunostaining in paediatric renal tumours.
Goyal S; Mishra K; Sarkar U; Sharma S; Kumari A
Indian J Med Res; 2016 May; 143(Supplement):S59-S67. PubMed ID: 27748279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
